-
High dose PPI infusion prior to endoscopy accelerated resolution of the signs of ulcer bleeding and significantly reduced the need for endoscopic hemostasis therapy.
-
Quinolone-resistant neisseria gonorrhea (QRNG) continues to spread with alarming frequency across the United States. Quinolones were first recommended for the treatment of GC by the CDC in 1986.
-
The FDA has approved a new combination product for the treatment of type 2 diabetes mellitus. Sitagliptin, the recently approved dipeptidyl peptidase-4 (DPP-4) inhibitor is combined with metformin in two different dose configurations. Sitagliptin/metformin is marketed by Merck & Co., Inc as Janumet.
-
A simple questionnaire can identify individuals at risk for chronic kidney disease.
-
A new class of drug has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) such as mycosis fungoides.
-
Persons who do not suffer hyperhidrosis (HID) may be surprised to learn that it has been associated with both occupational and physical impairment, as well as limitations in social interaction.
-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.
-
For women, up to 20% of all coronary events occur in the absence of traditional major risk factors, and many women with these risk factors do not develop coronary events.
-
Patients at high risk for VTE should be treated with three times daily UH, while patients at lower risk may be treated with twice daily therapy.
-
The ECG Figure in the article was obtained from an older woman who was seen in the Emergency Department with a chief complaint of weakness of several days duration.
